These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1529071)

  • 21. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selecting an interim analysis procedure.
    Overall JE; Atlas RS
    Psychopharmacol Bull; 1993; 29(2):141-7. PubMed ID: 8290658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothesis tests for population heterogeneity in meta-analysis.
    Viechtbauer W
    Br J Math Stat Psychol; 2007 May; 60(Pt 1):29-60. PubMed ID: 17535578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.
    Gould AL
    Stat Med; 1992 Jan; 11(1):55-66. PubMed ID: 1557576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Power of pairwise comparisons in the equal variance and unequal sample size case.
    Ramsey PH; Ramsey PP
    Br J Math Stat Psychol; 2008 May; 61(Pt 1):115-31. PubMed ID: 18482478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority.
    Koyama T; Sampson AR; Gleser LJ
    Stat Med; 2005 Aug; 24(16):2439-56. PubMed ID: 15977285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.